SkyDance Vascular
SkyDance Vascular
The OspreyIV deploys the catheter through the needle rather than over it. It is designed to protect the catheter at insertion, preserve the vessel, and create a new level of safety against needlestick injury.
Traditional over-the-needle catheters leave the catheter exposed to skin, vessel wall, and clinician at the moment of insertion. The scale of that exposure is significant.
Figures reflect SkyDance Vascular published materials. Source references available upon request.
In a traditional design, the catheter is mounted on the outside of the needle, so it contacts skin and vessel wall during insertion. The OspreyIV carries the catheter inside the needle, shielded until it is placed.
That single change is what makes every downstream benefit possible: higher first-attempt success, a barrier against contamination, and protected fluid delivery.
As the needle enters the vessel, so does the catheter, with no lowering or readvancing. Designed to promote high first-attempt success.
Deploying through the needle keeps the catheter from contacting skin flora, forming a physical barrier against insertion-related contamination.
Once the catheter is advanced, the needle retracts into the housing automatically and is permanently retained. No separate safety step.
An off-axis opening directs fluid toward the center of the vessel, away from the vein wall, reducing shear stress and chemical irritation.
The foundational through-the-needle platform for everyday peripheral access.
A closed configuration designed to limit blood exposure during placement.
Extended dwell access for patients who need a longer, vessel-preserving line.
Statements from clinicians who have reviewed or evaluated the OspreyIV. Attributions reflect SkyDance Vascular published materials.
Request clinical information, a product evaluation, or partnership details from the SkyDance Vascular team.
Both result from inflammation or penetration of the catheter into or through the venous wall, often from shear stress, chemical injury, or trauma at the time of insertion.
Addressed by Contoured Directional Flow
A shoulder in the traditional design changes push force, so practitioners may push against the vessel wall ineffectively. Across 371 patients, 27% required three or more attempts.
Addressed by Bevel Only Technique
The skin cannot be fully sterilized before insertion, and roughly 20% of skin flora lives below the surface. Over-the-needle catheters contact that flora directly, seeding colonization that can break free into the bloodstream.
Addressed by Skin Avoidance Technology
OSHA estimates 5.6 million healthcare workers are at risk of occupational exposure to bloodborne pathogens. As many as one-third of all sharps injuries happen during disposal of the device.
Addressed by Passive Needle Retraction
Figures reflect SkyDance Vascular published materials. Source references available upon request.
Including expanded CRBSI reporting for PIVs, PIV-related bloodstream infections, and a full clinical summary of the OspreyIV approach.
By deploying the catheter through the needle rather than over it, the OspreyIV protects the catheter at the single most vulnerable moment: insertion.
As the needle enters the vessel, so does the catheter, with no further advancement or repositioning.
The catheter deploys through the needle and never contacts skin, forming a physical barrier against contamination.
The needle automatically retracts into the housing once the catheter is advanced, and is permanently retained.
An off-axis opening delivers fluid away from the vein wall, minimizing shear stress and chemical irritation.
The foundational through-the-needle platform for everyday peripheral access.
A closed configuration designed to limit blood exposure during placement.
Extended dwell access for patients who need a longer, vessel-preserving line.
SkyDance Vascular is working to reduce the known complications that result from the traditional over-the-needle catheter design. The company has developed several inventive improvements, including Bevel Only Technique, Skin Avoidance Technology, Passive Needle Retraction, and Contoured Directional Flow.
The company is comprised of industry veterans with the expertise to develop, commercialize, and scale the business. The executive team has prior success selling startup businesses in the vascular access space, yielding large returns for investors.
Collective backgrounds span leading medical device, enterprise software, and vascular access organizations including St. Jude, C.R. Bard, Med-Comp, Medibuy.com, B. Braun, Vascular Pathways, Covidien, Lumitec, and Kimberly Clark.
Career medical device executive with 30+ years of success. Former Operating Partner at Altamont Capital, Group VP at CR Bard, and VP at Baxter Healthcare.
Leaders with prior exits in the vascular access space and backgrounds across St. Jude, C.R. Bard, Covidien, and B. Braun.
Board-certified specialists guiding clinical validation and adoption across adult, pediatric, and neonatal care.
Reach out for clinical information, partnership, investment, or employment.